Patents by Inventor Shuichi Furuya

Shuichi Furuya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100286063
    Abstract: In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.
    Type: Application
    Filed: May 7, 2010
    Publication date: November 11, 2010
    Inventors: Shuichi Furuya, Masami Kusaka
  • Patent number: 7622479
    Abstract: The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, R1b is a C6-10 aryl group which has substituent(s), and the like; Ta is a single bond, a C1-6 alkyl group, —CH2O—, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Za is a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a C6-10 aryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: November 24, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Oda, Takashi Imada, Kenichiro Naito, Toshiya Tamura, Shuichi Furuya
  • Patent number: 7569570
    Abstract: The present invention provides a thienopyrimidine compound, represented by the formula [wherein, R1 is C1-4 alkyl, R2 is (1) phenyl optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino, or (2) a heterocyclic group optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino and the like, R3 is a hydrogen atom or C1-4 alkyl, R4 is C1-4 alkyl optionally having a substituent such as C1-4 alkoxy-carbonyl, carboxyl, mono C1-4 alkylamino and N—C1-4 alkyl-N—C7-10 aralkylamino and the like] or a salt thereof, which has antagonistic action for gonadotropin-releasing hormone.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: August 4, 2009
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shuichi Furuya, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
  • Publication number: 20090169610
    Abstract: The present invention provides cancer treatment preparations of excellent targetability. The sugar chain-modified liposomes of the present invention, which contain an aromatase inhibitor, anti-androgenic agent, lyase inhibitor, GnRH agonist, GnRH antagonist, anti-angiogenic agent, tyrosine kinase inhibitor, serine-threonine kinase inhibitor, antibody having an anticancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine hydrochloride, oxaliplatin, prednisolone, tegafur-uracil mixtures, zinostatin stimalamer or arsenic trioxide may be used as cancer treatment preparations having an excellent targetability.
    Type: Application
    Filed: February 2, 2007
    Publication date: July 2, 2009
    Inventors: Noboru Yamazaki, Sei Yoshida, Masuo Yamaoka, Akira Hori, Shigeya Kakimoto, Shuichi Furuya
  • Publication number: 20090048273
    Abstract: The present invention provides a premature ovulation inhibitor for use in in vitro fertilization or embryo transfer process, which contains a nonpeptidic compound having a gonadotropin releasing hormone antagonistic action. The premature ovulation inhibitor for use in in vitro fertilization or embryo transfer process of the present invention is low toxic, permits oral administration, and has a superior inhibitory effect on premature ovulation in in vitro fertilization or embryo transfer process.
    Type: Application
    Filed: July 21, 2006
    Publication date: February 19, 2009
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Shuichi Furuya, Masami Kusaka
  • Publication number: 20070179097
    Abstract: In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.
    Type: Application
    Filed: March 27, 2007
    Publication date: August 2, 2007
    Inventors: Shuichi Furuya, Masami Kusaka
  • Publication number: 20050250793
    Abstract: It is intended to provide a preventing or treating agent for hot flash which comprises a nonpeptidic compound having gonadotropin releasing hormone antagonistic activity, in particular, a preventing or treating agent for hot flash which comprises a nonpeptidic compound having gonadotropin releasing hormone antagonistic activity, wherein said compound is capable of entering the brain.
    Type: Application
    Filed: April 10, 2003
    Publication date: November 10, 2005
    Inventors: Masami Kusaka, Shuichi Furuya
  • Patent number: 6962919
    Abstract: A compound of the formula: wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R1, R2 and R3 each is (i) H or (ii) a group bound via C, N, O or S; R4 is a group bound via C; R5 is H or a group bound via C or O; R6 is H or a group bound via C; R7 is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.
    Type: Grant
    Filed: January 11, 2002
    Date of Patent: November 8, 2005
    Assignee: Takeda Pharmaceutical Co., Ltd.
    Inventors: Shuichi Furuya, Toshihiro Imaeda, Satoshi Sasaki
  • Publication number: 20050222174
    Abstract: The present invention provides a thienopyrimidine compound, represented by the formula [wherein, R1 is C1-4 alkyl, R2 is (1) phenyl optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino, or (2) a heterocyclic group optionally having a substituent such as amino, mono C1-4 alkylamino and di C1-4 alkylamino and the like, R3 is a hydrogen atom or C1-4 alkyl, R4 is C1-4 alkyl optionally having a substituent such as C1-4 alkoxy-carbonyl, carboxyl, mono C1-4 alkylamino and N—C1-4 alkyl-N—C7-10 aralkylamino and the like] or a salt thereof, which has antagonistic action for gonadotropin-releasing hormone.
    Type: Application
    Filed: January 29, 2003
    Publication date: October 6, 2005
    Applicant: Takeda Chemical Industries Ltd.
    Inventors: Shuichi Furuya, Takashi Imada, Takenori Hitaka, Kazuhiro Miwa, Masami Kusaka, Nobuhiro Suzuki
  • Publication number: 20050215528
    Abstract: In the field of pharmaceuticals, it is intended to provide drugs whereby the preventive and therapeutic effects of a GnRH agonist on various diseases can be enhanced and QOL can be improved. More specifically, combination of drugs characterized in that the GnRH agonist is combined with a chemical selected from among SERM, SARM, sex hormone synthesis inhibitors, receptor-type tyrosine kinase inhibitors, bone metabolism regulators, drugs for immunotherapy, cytokine/chemokine inhibitors and endothelin receptor antagonists. Owing to these combinations, excellent effects of enhancing the preventive and therapeutic effects of the GnRH agonist on various diseases and relieving side effects can be established. Furthermore, QOL can be improved thereby.
    Type: Application
    Filed: August 8, 2002
    Publication date: September 29, 2005
    Inventors: Shuichi Furuya, Masami Kusaka
  • Publication number: 20050101647
    Abstract: The present invention provides a heterocyclic compound having potent tyrosine kinase-inhibiting activity represented by formula: (wherein, R1b is a C6-10 aryl group which has substituent(s), and the like; Ta is a single bond, a C1-6 alkyl group, —CH2O—, and the like; X and Y are the same or different, and each is a nitrogen atom which may have substituent(s), and the like; the broken line is a single bond or a double bond; Za is a nitrogen atom or CH; W is a single bond, an oxygen atom, and the like; Q is a C6-10 aryl group which may have substituent(s) or an aromatic heterocyclic group which may have substituent(s)); or a salt thereof and a pharmaceutical composition comprising thereof.
    Type: Application
    Filed: November 25, 2002
    Publication date: May 12, 2005
    Inventors: Tsuneo Oda, Takashi Imada, Kenichiro Naito, Toshiya Tamura, Shuichi Furuya
  • Publication number: 20050101657
    Abstract: The present invention provides an androgen receptor antagonistic agent and a superior prophylactic or therapeutic agent for hormone-sensitive cancer, which contain a compound of the formula: wherein, R1 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R2 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, R3 is a hydrogen atom, a hydrocarbon group which may have substituent(s), an acyl group or a heterocyclic group which may have substituent(s), R4 is a hydrogen atom, a group binding through a carbon atom, a group binding through a nitrogen atom, a group binding through an oxygen atom or a group binding through a sulfur atom, and R5 is a cyclic group which may have substituent(s); or a salt thereof, or its prodrug.
    Type: Application
    Filed: December 26, 2002
    Publication date: May 12, 2005
    Applicant: Takeda Chemical Industries Ltd.
    Inventors: Shuichi Furuya, Nobuyuki Matsunaga, Masami Kusaka, Takahito Hara, Junichi Miyazaki
  • Publication number: 20040138160
    Abstract: This invention provides a prophylactic or therapeutic method for cancer.
    Type: Application
    Filed: March 2, 2004
    Publication date: July 15, 2004
    Inventors: Kenichiro Naito, Shuichi Furuya, Akihiro Tasaka, Toshikazu Ban
  • Publication number: 20040116330
    Abstract: A method of controlling the growth and differentiation of cancer is provided.
    Type: Application
    Filed: February 5, 2004
    Publication date: June 17, 2004
    Inventors: Kenichiro Naito, Shuichi Furuya, Akihiro Tasaka, Toshikazu Ban
  • Publication number: 20030134863
    Abstract: The present invention provides an agent for the prophylaxis or treatment of Alzheimer's disease. The agent for the prophylaxis or treatment of Alzheimer's disease of the present invention containing a compound having a GnRH antagonistic action shows low toxicity and has a superior preventive and therapeutic effect on Alzheimer's disease.
    Type: Application
    Filed: October 3, 2002
    Publication date: July 17, 2003
    Inventors: Shuichi Furuya, Nobuhiro Suzuki
  • Patent number: 6514988
    Abstract: A gonadotropin-releasing hormone antagonistic composition, which comprises an optionally substituted condensed-bicyclic compound consisting of a homo or hetero 5 to 7 membered ring and a homo or hetero 5 to 7 membered ring is effective as a propylactic or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, cancer of uterine cervix, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, pplycystic ovary syndrome and acne vulgaris; is effective as a fertility controlling agent in both sexes (e.g.
    Type: Grant
    Filed: September 29, 2000
    Date of Patent: February 4, 2003
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Shuichi Furuya, Nobuo Choh, Koichi Kato, Shuji Hinuma
  • Publication number: 20020198384
    Abstract: The present invention provides an intermediate for producing a thienopyridine derivative useful as a GnRH antagonist as well as an efficient and safe method for producing the same in an industrial scale at a high yield.
    Type: Application
    Filed: June 3, 2002
    Publication date: December 26, 2002
    Inventors: Shokyo Miki, Koichiro Fukuoka, Masahiro Akita, Junichi Kawakami, Shuichi Furuya, Yoichiro Ishimaru
  • Publication number: 20020170827
    Abstract: A multilayer substrate for a buildup with a via, which multilayer substrate comprises a base material comprising an insulation resin layer on which a predetermined hole is formed,
    Type: Application
    Filed: February 27, 2002
    Publication date: November 21, 2002
    Inventor: Shuichi Furuya
  • Publication number: 20020103210
    Abstract: A compound of the formula: 1
    Type: Application
    Filed: January 11, 2002
    Publication date: August 1, 2002
    Applicant: TAKEDA CHEMICAL INDUSTRIES, LTD.
    Inventors: Shuichi Furuya, Toshihiro Imaeda, Satoshi Sasaki
  • Patent number: 6413972
    Abstract: A compound of the formula: wherein one of A and D is N and the other is C, or both are N; B is N or C; m is 0-3; R1, R2 and R3 each is (i) H or (ii) a group bound via C, N, O or S; R4 is a group bound via C; R5 is H or a group bound via C or O; R6 is H or a group bound via C; R7 is a homo- or hetero-cyclic group which may be substituted; or a salt thereof possesses excellent gonadotropin-releasing hormone antagonizing activity, and is useful as a prophylactic or therapeutic agent for sex hormone-dependent diseases, and so forth.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: July 2, 2002
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Shuichi Furuya, Toshihiro Imaeda, Satoshi Sasaki